资讯

Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.